IRF5 regulates airway macrophage metabolic responses.


Journal

Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202

Informations de publication

Date de publication:
04 2021
Historique:
received: 04 10 2020
revised: 13 12 2020
accepted: 16 12 2020
pubmed: 11 1 2021
medline: 28 9 2021
entrez: 10 1 2021
Statut: ppublish

Résumé

Interferon regulatory factor 5 (IRF5) is a master regulator of macrophage phenotype and a key transcription factor involved in expression of proinflammatory cytokine responses to microbial and viral infection. Here, we show that IRF5 controls cellular and metabolic responses. By integrating ChIP sequencing (ChIP-Seq) and assay for transposase-accessible chromatin using sequencing (ATAC)-seq data sets, we found that IRF5 directly regulates metabolic genes such as hexokinase-2 (Hk2). The interaction of IRF5 and metabolic genes had a functional consequence, as Irf5

Identifiants

pubmed: 33423291
doi: 10.1111/cei.13573
pmc: PMC7944363
doi:

Substances chimiques

Interferon Regulatory Factors 0
Toll-Like Receptor 3 0
Sirt6 protein, mouse EC 2.4.2.31
Hexokinase EC 2.7.1.1
hexokinase 2, mouse EC 2.7.1.1
Sirtuins EC 3.5.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

134-143

Subventions

Organisme : Wellcome Trust
ID : 209422/Z/17/Z
Pays : United Kingdom
Organisme : Asthma UK
ID : AUK-SNF-2017- 381
Organisme : Wellcome
ID : 107059/Z/15/Z
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 100156/Z/12/Z
Pays : United Kingdom

Informations de copyright

© 2021 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology.

Références

Nat Immunol. 2014 Nov;15(11):1026-37
pubmed: 25263125
Mucosal Immunol. 2016 Mar;9(2):550-63
pubmed: 26422753
J Exp Med. 2020 Mar 2;217(3):
pubmed: 31917836
J Am Coll Cardiol. 2014 Apr 22;63(15):1556-66
pubmed: 24361318
Cell. 2019 Feb 7;176(4):897-912.e20
pubmed: 30686579
Cell Rep. 2014 Sep 11;8(5):1308-17
pubmed: 25159141
Mucosal Immunol. 2017 May;10(3):716-726
pubmed: 27759022
Nat Rev Immunol. 2016 Sep;16(9):553-65
pubmed: 27396447
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11001-6
pubmed: 26283380
Nat Immunol. 2019 May;20(5):571-580
pubmed: 30936493
Cell Death Differ. 2015 Feb;22(2):248-57
pubmed: 25323588
PLoS Pathog. 2014 Apr 03;10(4):e1004053
pubmed: 24699679
Mucosal Immunol. 2021 Mar;14(2):282-295
pubmed: 33184475
Nat Immunol. 2011 Mar;12(3):231-8
pubmed: 21240265
Am J Respir Crit Care Med. 2019 Jul 15;200(2):209-219
pubmed: 31051082
JCI Insight. 2017 May 18;2(10):
pubmed: 28515358
Trends Immunol. 2017 Jun;38(6):395-406
pubmed: 28396078
Am J Respir Cell Mol Biol. 2020 Feb;62(2):243-255
pubmed: 31469581
Nat Biotechnol. 2010 May;28(5):495-501
pubmed: 20436461
J Virol. 1997 Dec;71(12):9450-7
pubmed: 9371606
Mediators Inflamm. 2013;2013:245804
pubmed: 24453413
Sci Rep. 2019 Dec 11;9(1):18801
pubmed: 31827178
Thorax. 2015 Dec;70(12):1189-96
pubmed: 26286722
Sci Immunol. 2020 Oct 23;5(52):
pubmed: 33097591

Auteurs

G J Albers (GJ)

Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College London, London, UK.

J Iwasaki (J)

Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College London, London, UK.

P McErlean (P)

Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College London, London, UK.

P P Ogger (PP)

Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College London, London, UK.

P Ghai (P)

Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College London, London, UK.

T E Khoyratty (TE)

The Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.

I A Udalova (IA)

The Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.

C M Lloyd (CM)

Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College London, London, UK.

A J Byrne (AJ)

Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH